More than 2.5 million breast cancer survivors live in the US today. This number will continue to grow thanks to early detection and advances in treatment that are making early stage breast cancer an increasingly curable disease. None of these gains in survival, however, have come without cost, especially as treatment complexity increases. Long-term effects of treatment, which are complications that begin during treatment and continue beyond the end of treatment, occur as a result of breast cancer therapies and are increasingly prevalent in breast cancer survivors.
Younger women with breast cancer often receive very complex breast cancer treatment regimens, and thus are at risk for a host of various adverse effects. Nowadays, one in three women newly diagnosed with breast cancer is younger than 55 years of age. One of the most common side effects in women with breast cancer, including younger women, is cancer treatment–induced bone loss (CTIBL), which often leads to osteopenia and/or osteoporosis.
In the general US population, more than 8 million women have osteoporosis, a condition characterized by decreased bone strength. Vertebral, hip, and other bone fractures are the chief clinical manifestations of this disease. A Caucasian woman's lifetime risk of osteoporotic fracture is as high as 45%, with these fractures causing significant morbidity and substantial economic consequences. Women with a breast cancer diagnosis are at increased risk for developing both osteoporosis and related fracture,[8,9] in large part due to the substantial role that estrogen plays in bone metabolism.
In women, estrogen protects against bone loss and reduces bone turnover by decreasing the formation, activation, and lifespan of osteoclasts, the cells responsible for breaking down bone. As levels of estrogen decrease, whether due to natural or iatrogenic declines in ovarian function or other treatment effects, bone resorption exceeds new bone formation, leading to net bone loss. Through a variety of mechanisms, treatments for breast cancer interfere with the positive effects of estrogen on bone metabolism, thereby inducing accelerated rates of bone loss.
1. Ries L, et al: SEER Cancer Statistics Review, 1975-2005 [cited May 15, 2008]. Available at: http://seer.cancer.gov/csr/1975_2005/. Accessed on March 20, 2010.
2. Hewitt M, Greenfield S, Stovall E: From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC, The National Academies Press, 2006.
3. Partridge AH, Winer EP: Long-term complications of adjuvant chemotherapy
for early stage breast cancer. Breast Dis 21:55-64, 2004.
4. World Health Organization: Prevention and Management of Osteoporosis: Report of a WHO Scientific Group. WHO Technical Report Series 2003. April 20, 2006. Available at: http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf. Accessed on March 15, 2010.
5. Boonen S, et al: Effect of osteoporosis treatments on risk of non-vertebral
fractures: Review and meta-analysis of intention-to-treat studies. Osteoporosis
Int 16(10):1291–1298, 2005.
6. Cummings SR, Bates D, Black DM: Clinical use of bone densitometry: Scientific
review. JAMA 288(15):1889–1897, 2002. [See erratum in JAMA 288(22):2825,
7. Bringhurst FR, et al: Bone and Mineral Metabolism in Health and Disease,
in Kasper DL, et al (eds): Harrison's Internal Medicine. New York,
8. Theriault R, et al: NCCN Task Force Report: Bone Health and Cancer Care.
J Nat Comp Cancer Network 4(suppl 2):S1–S20, 2006.
9. Winer EP, et al: Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004. Available at: http://www.asco.org/ac/1,1003,_12-002033-00_18-0036744-00_19-0036745-00_20-001,00.asp.
10. Love RR, et al: Effects of tamoxifen on bone mineral density bone mineral
density in post-menopausal women with breast cancer. N Engl J Med
11. Ahlborg HG, et al: Bone loss and bone size after menopause [See comment].N
Engl J Med 349(4):327–334, 2003.
12. Saarto T, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients.
J Clin Oncol 15(4):1341–1347, 1997.
13. Vehmanen L, et al: Tamoxifen treatment after adjuvant chemotherapy
has opposite effects on bone mineral density in premenopausal patients depending
on menstrual status. J Clin Oncol 24(4):675–680, 2006.
14. Brunin PF, et al: Bone mineral density after adjuvant chemotherapy
for premenopausal breast cancer. Brit J Cancer 61(2): 308–310,
15. Vehmanen L, et al: Short-term intermittent intravenous clodronate in
the prevention of bone loss related to chemotherapy-induced ovarian failure.
Breast Ca Res Treat 87(2):181–188, 2004.
16. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy
is associated with rapid bone loss in women with early-stage breast cancer
[see comment]. J Clin Oncol 19(14):3306–3311, 2001.
17. Saarto T, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients.
J Clin Oncol 15(4):1341–1347, 1997.
18. Genant HK, et al: Quantitative computed tomography of vertebral spongiosa:
A sensitive method for detecting early bone loss after oophorectomy. Ann
Intern Med 97(5):699–705, 1982.
19. Vehmanen L, et al: Long-term impact of chemotherapy-induced ovarian
failure on bone mineral density (BMD) in premenopausal breast cancer patients.
The effect of adjuvant clodronate treatment. Eur J Cancer 37(18):2373–2378,
20. Fisher B, et al: Tamoxifen for prevention of breast cancer: Report
of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [see
comment]. J Natl Cancer Inst 90(18):1371–1388, 1998.
21. Sverrisdottir A, et al: Bone mineral density among premenopausal women
with early breast cancer in a randomized trial of adjuvant endocrine therapy.
J Clin Oncol 22(18):3694–3699, 2004.
22. Eastell R, Hannon R: Long-term effects of aromatase inhibitors on bone.
J Steroid Biochem Molec Biol 95(1-5):151–154, 2005.
23. Baum M, et al: Anastrozole alone or in combination with tamoxifen versus
tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage
breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination)
trial efficacy and safety update analyses. Cancer 98(9):1802–1810,
24. Coombes RC, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
N Engl J Med 350(11):1081–1092, 2004.
25. Goss PE, et al: A randomized trial of letrozole in postmenopausal women
after five years of tamoxifen therapy for early-stage breast cancer. N
Engl J Med 349(19):1793–1802, 2003.
26. Perez EA, et al: Effect of letrozole versus placebo on bone mineral
density in women completing >5 years of adjuvant tamoxifen: NCIC CTG
MA-17B. Breast Ca Res Treat 88(Suppl 1):S36, 2004.
27. Lonning PE, et al: Effects of exemestane administered for 2 years versus
placebo on bone mineral density, bone biomarkers, and plasma lipids in patients
with surgically resected early breast cancer [see comment]. J Clin Oncol
28. Howell A: Effect of anastrozole on bone mineral density: 2-year results
of the ‘Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC)
trial. Breast Ca Res Treat 82(suppl 1):S27, 2003.
29. Coleman RE, et al: Intergroup Exemestane Study: 1 year results of the
bone subprotocol, in 27th Annual San Antonio Breast Cancer Symposium. Breast
Ca Res Treat 88:S35, 2004.
30. Eastell R, et al: Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
J Clin Oncol 26(7):1051–1057, 2008.
31. Chlebowski RT, Tagawa T: Early breast and prostate cancer and clinical
outcomes (fracture). Oncology (Williston Park) 23(14, suppl 5):16–20,
32. Hamdy RC, et al: Review of treatment modalities for postmenopausal
osteoporosis. South Med J 98(10):1000–1014, 2005.
33. Hillner BE, et al: American Society of Clinical Oncology 2003 update
on the role of bisphosphonates and bone health issues in women with breast
cancer. J Clin Oncol 21(21):4042–4057, 2003. [See erratum in J
Clin Oncol 22(7):1351, 2004.]
34. U.S.P.S.T.F.: Screening for osteoporosis in postmenopausal women: Recommendations
and rationale. Ann Intern Med 137(6):526–528, 2002.
35. Lindsay R, Cosman F: Osteoporosis, in Kasper DL, et al (eds): Harrison's Internal Medicine. New York, McGraw-Hill, 2005, pp 2268–2278.
36. National Osteoporosis Foundation: NOF Physician's Guidelines, 2008. Available at: http://www.nof.org/professionals/clinical.htm. Accessed on March 20, 2010.
37. National Osteoporosis Foundation: Calcium and Vitamin D Recommendations, 2008. Recommended calcium intakes. Available at: http://www.nof.org/prevention/calcium.htm. Accessed on March 20, 2010.
38. Kanis JA, et al: The use of clinical risk factors enhances the performance
of BMD in the prediction of hip and osteoporotic fractures in men and women.
Osteoporosis Int 18(8):1033–1046, 2007.